There’s always a lot of time and attention focused around phase 3 clinical trial readouts at ASCO, but what about some of the hidden gems where we can learn quite a bit from earlier developments?
This is a two-part series this week where we go off the beaten track on the road less travelled to explore some novel approaches, which may or may not make an impact.
Don’t forget we can often learn as much from negative studies as we do from positive ones because they can teach us what not to do in terms of future design of anti-cancer therapies.
New product development is very much a process of Kaizen, or continuous improvement where we adapt both from what went less well as well as what worked really well.
This year’s ASCO data drop has some important lessons embedded within for those intrigued to dig deeper and pay attention to the finer details…